Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net ...

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 – – KPL-387 Phase 1 single ascendin ...

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 - - KPL-387 Phase 1 single ascending dose data support potential monthly dosing - - Kiniksa contin ...

Ever wonder how celebrities always seem red carpet ready? Melanie Speed of Flawless Med Spa shares some insight.

New therapeutic 'cocktails' may provide long-lasting relief for treatment-resistant asthma and other immune system inflammatory diseases.

Current asthma treatments don't work in all patients, and they don't provide long-term relief from potentially deadly asthma ...

Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. Find out why I rate CADL stock ...

Discover effective natural remedies for constipation relief, from hydration and fiber-rich foods to movement strategies and ...

Global conditions are more favourable, supporting firmer economic growth in sub-Saharan Africa, financial organisation ...

If you’ve ever noticed your child rocking, flapping their hands, or repeating sounds over and over, you might have wondered ...

Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report) is expected to issue its quarterly earnings data before the market ...